Evolent Health 3Q 2026: Revenue $725.37M, EPS ($0.21) — 10-Q Summary
Evolent Health reported 3Q 2026 revenue of $725.37M, up 51.3% YoY, with a net loss of $0.21 per share. Growth came from new contracts and expanded services, offset by lower membership and rate adjustments. Higher claims costs increased the medical expense ratio to 93.0%.
How this was made
The 30-second read
Why it matters
The earnings beat on revenue and loss narrowing provides a short‑term bullish catalyst, but rising expense ratios signal margin pressure.
Market read
The earnings release offers a fresh data point for traders; the mix of strong top‑line growth and cost pressures creates a nuanced trade view.
What to watch
Potential slowdown in membership fees and contract rate adjustments may weigh on future margins.
Background
Evolent Health (EVH) filed its Q3 2026 Form 10‑Q, revealing a 51% YoY revenue increase driven by new Performance Suite contracts and expanded oncology services.
Ticker impact
The 10‑Q reports Q3 revenue of $725.37M, up 51.3% YoY, and a narrowed net loss, marking the first public disclosure of these figures.
likely modest upside as the market prices in revenue beat, tempered by margin pressure from rising claims costs
Strong top‑line growth is a positive catalyst, while the increase in medical expense ratio introduces downside risk.
Market effects
Positive revenue trends may lift other health‑tech and managed‑care service providers.
U.S. healthcare services sector could see modest buying pressure.
Limited to U.S. health‑tech investors; no broader macro impact.
Counterpoint
Higher claims costs could erode profitability, prompting a sell‑off despite revenue growth.
Key entities
- companyEvolent Health, Inc.
U.S. health‑technology firm reporting Q3 2026 results.
